How does the covid 19 vaccine impact cosentyx's efficacy?

Question

Accepted Answer

Short answer

The COVID‑19 vaccine does not diminish the long‑term efficacy of Cosentyx (secukinumab). Patients can receive the vaccine at any point in their biologic schedule without having to pause or adjust their Cosentyx dose. The most common effect is a brief, transient flare of the underlying skin or joint inflammation, but that is usually mild and self‑limited.

What we know

Topic	What the science tells us
How Cosentyx works	Secukinumab blocks interleukin‑17A (IL‑17A), a key cytokine driving the inflammatory cascade in psoriasis and psoriatic arthritis.
How COVID‑19 vaccines work	Most approved vaccines (mRNA, viral vector, protein subunit) stimulate the immune system to produce neutralising antibodies and T‑cell responses against the SARS‑CoV‑2 spike protein.
Effect on Cosentyx’s mechanism	Blocking IL‑17A does not interfere with the vaccine’s ability to generate an immune response, and the vaccine’s cytokine release does not alter IL‑17A inhibition.
Clinical data	1. A pooled analysis of patients on IL‑17 inhibitors (including secukinumab) who received COVID‑19 vaccines reported no reduction in disease control and only transient flares in ~10‑15 % of patients. 2. No serious safety signals or loss of efficacy have been observed in registries of biologic users who were vaccinated.
Guidelines	• The American Academy of Dermatology (AAD) and the European Dermatology Forum (EDF) both recommend that biologic therapy (including secukinumab) should continue unchanged around COVID‑19 vaccination. • If a flare occurs, it is usually manageable with a short‑term dose‑escalation of topical steroids or a temporary pause of the vaccine interval, not by altering Cosentyx dosing.
Immune response to vaccine	While biologics can modestly reduce humoral (antibody) responses to some vaccines, secukinumab has not been shown to significantly blunt the antibody titre to mRNA vaccines. Patients still develop robust protection, though real‑world data are limited.

Practical take‑away for patients on Cosentyx

Scenario	Recommendation
You’re due for a COVID‑19 booster	Schedule the booster before the next scheduled Cosentyx dose if possible, but it’s fine to get it on the same day or a day apart. The biologic does not need to be stopped.
You notice new or worsening rashes after vaccination	This is usually a mild flare. Apply topical steroids or contact your dermatologist if it persists beyond a week. No need to change your Cosentyx dose.
You’re worried about vaccine safety	Cosentyx does not increase vaccine‑related adverse events. The vaccine’s benefits far outweigh any theoretical risk of a flare.
You’re concerned about vaccine‑induced antibody levels	Your dermatologist can discuss additional precautions (e.g., a third dose) if you have high‑risk comorbidities, but the vaccine remains effective while on secukinumab.

Bottom line

Cosentyx efficacy stays intact after receiving a COVID‑19 vaccine.
A brief, mild flare of psoriasis or psoriatic arthritis can occur, but it does not require stopping or altering your secukinumab therapy.
Vaccination is still strongly recommended for patients on biologics, and no special adjustment of the biologic regimen is needed.

Quick FAQ

Question	Answer
Do I need to stop Cosentyx before vaccination?	No. Keep your regular dosing schedule.
Will the vaccine reduce my skin disease control?	No documented evidence of reduced control.
Will I have a weaker response to the vaccine?	Current data show no significant reduction in antibody response with secukinumab.
What if I get a flare after the shot?	Use topical steroids or brief dose‑escalation; no change to Cosentyx required.

If you have any specific concerns about your dosing schedule or side‑effects, please talk with your dermatologist or rheumatologist—they can tailor advice to your exact treatment plan.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

How does the covid 19 vaccine impact cosentyx's efficacy?

Short answer

What we know

Practical take‑away for patients on Cosentyx

Bottom line

Quick FAQ